← Human Trials & Peer-Reviewed Studies
Physiological role of cholecystokinin in gastroprotection in humans
Plain-language guide to PMID 9860397 (1998): double-blind randomized controlled trial study of Cholecystokinin (CCK) and Sincalide in 16 volunteers.
Key Facts
- PMID
- 9860397
- Journal
- The American journal of gastroenterology
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Konturek JW et al. (6 authors)
- DOI
- 10.1111/j.1572-0241.1998.00692.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Cholecystokinin (CCK) and Sincalide.
Cholecystokinin (CCK) is able to protect gastric mucosa against acute injury in experimental animals but little is known about the role of this hormone in maintaining mucosal integrity in humans.
This double-blind, placebo controlled study was performed in 16 healthy volunteers.
Who Took Part
The abstract describes 16 volunteers taking part.
The age groups tagged for this paper are adults, men only.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Cholecystokinin (CCK) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the volunteers and researchers unaware of who received Cholecystokinin (CCK).
Some volunteers received a placebo instead of Cholecystokinin (CCK), giving a reference point.
CCK-8 was infused i.v. 30 min before and throughout the study or i.d. oleate was instilled through a separate duodenal tube.
Gastroscopy was performed and mucosal lesions were quantified using modified Lanza score.
Gastric biopsies were taken from oxyntic mucosa for histological evaluation and gastric content was aspirated for radioimmunoassay of somatostatin.
What Was Measured
Topics PubMed links to this paper include Cholecystokinin, Duodenum, Ethanol, Gastric Mucosa, Gastroscopy, Hormone Antagonists and Oleic Acid.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) and Sincalide in 16 volunteers.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1998 (The American journal of gastroenterology), a journal based in United States.
More context: the Cholecystokinin (CCK) compound page and the Sincalide compound page, all human trials.
Our Notes on the Compounds
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Sincalide: A synthetic 8-amino-acid fragment of cholecystokinin (Kinevac) used in gallbladder and pancreas imaging.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.